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Abstract
Decisions in healthcare should be based on information obtained according to the principles of Evidence-Based 
Medicine (EBM). An increasing number of systematic reviews are published which summarize the results of prevalence 
studies. Interpretation of the results of these reviews should be accompanied by an appraisal of the methodological 
quality of the included data and studies. The critical appraisal tool for prevalence studies developed and tested by 
Munn et al. comprises 10 items and aims at targeting all kinds of prevalence studies. This comment discusses the 
pros and cons of different designs of quality appraisal tools and highlights their importance for systematic reviews of 
prevalence studies. Beyond piloting, which has been performed in the study by Munn et al., it is suggested here that 
the validity of the tool should be tested, including reproducibility and inter-rater reliability. It is concluded that studies 
as the one by Munn et al. will help to establish a critical understanding of methodological quality and will support the 
use of systematic reviews of non-intervention studies for health policy making.
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During recent years, it has become more and more accepted that decisions in healthcare have to be based on information obtained according to the principles 
of Evidence-Based Medicine (EBM) (1,2). Traditionally, 
EBM methodology has focused on systematic reviews of 
intervention studies. However, an increasing number of 
systematic reviews are published which summarize the 
results of prevalence studies, and specific techniques have 
been developed for meta-analysis (synthesis) of this kind 
of data (3).  
Systematically searching and reviewing evidence on 
prevalence of disease is important for a variety of reasons: 
• Prevalence studies are used to inform researchers, 
guideline developers and policy-makers about burden of 
disease, thereby supporting the process of identification 
of priorities in healthcare, prevention and policy. 
• Prevalence studies are needed for the development of 
health economics models. It has become more and more 
accepted that modelling studies should be conducted to 
assess the economic impact of an intervention before its 
implementation in a patient group or population. Input 
parameters needed for modelling studies such as the 
prevalence of a disease or complication can have a great 
impact on the results. 
• Prevalence studies inform the assessment of 
interventions, since they provide data on the baseline risk 
for a given disease in a patient group or population which 
influences effect measures (4).
However, evidence does not speak for itself (5). It needs to 
be interpreted critically, with reviewers being aware of the 
strength and limitations of the data. Interpretation should be 
accompanied by an appraisal of the methodological quality 
of the data and studies. Therefore, a variety of tools and 
checklists have been developed to support the process of 
critical appraisal of single studies [for an overview, see (6–9)]. 
In this context, it is important to clarify the definition of 
‘methodological quality’. The Agency for Healthcare Research 
and Quality (AHQR) defines methodological quality as the 
extent to which a study’s design, conduct, and analysis has 
minimized selection, measurement, and confounding biases 
(8). Applying this definition, the term “methodological 
quality” is used interchangeably with “risk of bias” or 
“internal validity”. However, many critical appraisal tools also 
incorporate items related to external validity, which might 
be important if results from a study should be transferred to 
another country or setting. 
The new tool for the critical appraisal of prevalence studies 
developed and tested by Munn et al. (10) comprises 10 items. 
In addition, the authors provide an appendix with detailed 
descriptions and explanations which will be helpful for those 
users who are not familiar with critical appraisal tools. The 
tool includes items related to the internal validity of the study 
(e.g. were study participants recruited in an appropriate 
way?), but also some on external validity (e.g. was the sample 
representative of the target population?). If one compares 
the tool to those which are already available for assessment 
of prevalence studies, some similarities but also differences 
become apparent. While the number of items/criteria used is 
very similar to other tools [e.g. Hoy et al. (11): 10 items; Loney 
et al. (12): 8 items], the tool by Munn et al. strictly focusses 
on validity and does not assess reporting quality, which is 
incorporated in some other tools such as the one developed by 
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the National Collaborating Centre for Environmental Health 
(NCCEH) (13). In general, it is important to distinguish 
between methodological quality and the transparency and 
quality of reporting (9) since it has been shown that studies 
with similar reporting quality may be different regarding 
methodological quality (14). Furthermore, the tool by 
Munn et al. differs from others regarding the study types to 
be covered. A recent methodological study concluded that 
quality appraisal tools are often designed to address a certain 
study type, rather than a research question (8). For example, 
the consequences of an intervention can be either studied 
by Randomized Controlled Trials (RCTs) or observational 
studies. In RCTs, blinding of participants and observers is an 
important issue which is addressed by many critical appraisal 
tools, such as the Cochrane Risk of Bias Tool (15). Without 
adequate blinding, the validity of the trial can be seriously 
damaged. However, the same intervention effects can also 
be addressed by other study types, such as non-randomized 
controlled trials, or even cohort studies or case-control 
studies, although these study designs are not ideal for these 
questions. For different study designs, other issues which 
are specific for those study designs become important, such 
as the process of selection of controls. They are addressed 
by tools specifically designed for case-control studies, such 
as the Newcastle-Ottawa Scale (NOS) (16). However, some 
quality appraisal tools exist which aim to cover a large variety 
of study designs, such as the one developed by Cho et al. (17) 
which was designed to cover intervention as well as non-
intervention studies. The tool reported by Munn et al. aims 
at targeting all kinds of studies reporting prevalence data. It 
remains to be investigated whether tools designed to cover a 
specific study design provide more transparent results and are 
easier to apply than those critical appraisal tools that aim at 
covering more than one study design. 
Two subsequent steps are important when a new quality 
appraisal tool has been developed. First, it is necessary to pilot 
the tool, in order to test its applicability and user friendliness. 
This step has been performed by Munn et al. and the results 
look promising, as described in their paper. The second step, 
however, is of equal importance. The validity of the tool 
should be tested, including reproducibility and inter-rater 
reliability. In fact, only a minority of the so far published 
quality appraisal tools has been validated (8), but validation 
is important for further improvement of the tools (16,18). 
Munn et al. should consider performing such a validation 
study which will surely support the acceptance of their tool by 
the scientific community.
Last but not least, more studies like the one reported by Munn 
et al. are needed on the usage and applicability of critical 
appraisal tools. Such research will help to establish a critical 
understanding of methodological quality and will support 
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